Pembrolizumab for adjuvant treatment of completely resected stage 3 melanoma

2.1 Pembrolizumab (Keytruda, MSD) is indicated 'for the adjuvant treatment of adults with Stage III melanoma and lymph node involvement who have undergone complete resection'.

2.2 The dosage schedule is available in the summary of product characteristics for pembrolizumab.

2.3 The list price is £2,630.00 per 100 mg/4 ml concentrate for solution for infusion vial (excluding VAT; BNF online, accessed November 2021). The company has a commercial arrangement. This makes pembrolizumab available to the NHS with a discount. The size of the discount is commercial in confidence. It is the company's responsibility to let relevant NHS organisations know details of the discount.